(Journal Article): Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
 
Zander M, Madsbad S, Madsen JL, Holst JJ
 
IN: Lancet 2002; 359(9309):824-830
Impact Factor(s) of Lancet: 23.407 (2005), 21.713 (2004), 18.316 (2003), 15.397 (2002), 13.251 (2001)

ABSTRACT: BACKGROUND: Glucagon-like peptide 1 (GLP-1) has been proposed as a treatment for type 2 diabetes. We have investigated the long-term effects of continuous administration of this pe... Click HERE for details